QualityStocksNewsBreaks Archives - Page 311 of 1613

MondayAug 19, 2024 11:05 am

QualityStocksNewsBreaks – Upstream Provides 24/7 Ability to Transact on All Issuers’ Listed Equities

Upstream, a MERJ Exchange stock market and global trading app, is reporting three key benefits from expanded trading hours, including flexibility during market sell-offs, accessibility for global investors and interconnectivity of global markets. The Upstream article noted that traditional markets operate within specific trading windows, which creates some challenges. “U.S. markets open at 9:30 a.m. ET and close at 4 p.m. ET, and international markets, such as the London Stock Exchange, operate from 8 a.m. to 4:30 p.m. GMT,” stated the article. “When traditional markets like these are closed during times of volatility, particularly sell-offs, investors in different time zones…

FridayAug 16, 2024 3:12 pm

QualityStocksNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089 Showing Great Promise in Treating AMD

InMed Pharmaceuticals (NASDAQ: INM), a clinical stage company developing a pipeline of pharmaceutical drug candidates to treat several diseases with a high unmet medical need, is at the forefront of developing innovative treatment for age-related macular degeneration (“AMD”), with its flagship product INM-089 showing great promise. “AMD is a prevalent eye condition that primarily affects older adults, leading to vision loss in the central part of the retina, known as the macula… AMD is the leading cause of vision loss among people aged 50 and older. It comes in two forms: dry AMD, which is more common and less severe,…

FridayAug 16, 2024 2:30 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Opportunity from First-Ever Work with Tirzepatide Molecule

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently hired a Contract Research Organization (“CRO”) for its third human pilot study. “This marks a milestone for the company, notably since it announced its focus solely on glucagon-like peptide 1 (‘GLP-1’) studies for the 2024 calendar year… This randomized, crossover investigation will evaluate a dual-action GLP-1 + glucose-dependent insulintropic peptide (‘GIP’), specifically measuring absorption, tolerability, pharmacokinetics, and blood sugar levels. It will compare injected tirzepatide (Zepbound(R) by Eli Lilly) to a compound formulated, DehydraTECH-processed tirzepatide derived from Zepbound(R). The objective would be to evaluate whether DehydraTECH-processed tirzepatide,…

FridayAug 16, 2024 2:00 pm

QualityStocksNewsBreaks – Correlate Energy Corp. (CIPI) Addressing ‘Significant Problem’ with Resilient Energy Solutions

Correlate (OTCQB: CIPI), a tech-enabled development, finance and fulfillment platform for distributed energy solutions across North America, is driving scalability in the microgrid energy distribution market. This follows a new partnership between its subsidiary Distributed Energy Capital (“DEC”) and clean energy development innovator Compass Energy that will establish the United States’ first microgrid utility. “The landmark initiative by Distributed Energy Capital and Compass Energy Platform to adopt renewable utility infrastructure is for Ohio’s Cuyahoga County. The county formed Cuyahoga Green Energy (‘CGE’) three years ago as a utility focused entirely on renewable energy and resiliency. CGE’s project differs from traditional…

FridayAug 16, 2024 9:58 am

QualityStocksNewsBreaks – HealthLynked Corp. (HLYK) Announces Q2, H1 2024 Financial Results Reflecting Efforts to Streamline Operations

HealthLynked (OTCQB: HLYK), a trailblazer in healthcare technology, today announced financial results for its Q2 and H1 2024 ending June 30, 2024. The announcement noted that the company achieved significant cost reductions, leading to an 8% quarter-over-quarter improvement in its loss from operations to $1.08 million in Q2 2024 from $1.18 million in Q1 2024. This improvement reflects HealthLynked’s ongoing efforts to streamline operations and transition its revenue streams from legacy clinical operations to app-based services. In addition, the company reported revenue of $0.78 million in Q2 2024 and $1.80 million in H1 2024. Its total operating expenses decreased by…

FridayAug 16, 2024 9:45 am

QualityStocksNewsBreaks – Starco Brands Inc. (STCB) Board Approves Insider Trading Policy, Shares Plans to Buy Back Stock

Starco Brands (OTCQB: STCB), a developer and acquirer of behavior-changing technologies and brands that spark excitement in the everyday, has announced approval by its board of the company’s Insider Trading Policy and plans for insiders to buy-back stock. The announcement noted that all five of the company’s portfolio brands have seen year-to-date growth, with two of the divisions expected to double year over year through 2024. “As our public company continues to grow and gain in popularity, the employees and senior executives are eager to own more of our stock,” said Starco Brands chair and CEO Ross Sklar in the…

ThursdayAug 15, 2024 2:40 pm

QualityStocksNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Announces Completion of Name Change, Begins Trading Under New Symbol

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), formerly FSD Pharma Inc., a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has finalized its previously announced name change and consolidation. According to the announcement, the company’s class B subordinate voting shares began trading today under the new ticker symbol QNTM. In addition, the company closed on a nonbrokered private placement and issued four postconsolidation Class A multiple voting shares for $18 per share, resulting in gross proceeds of $72. Xorax Family Trust, a trust of which Quantum BioPharma CEO and cochair Zeeshan Saeed is a beneficiary,…

ThursdayAug 15, 2024 1:47 pm

QualityStocksNewsBreaks – Actuate Therapeutics, Inc. (NASDAQ: ACTU) Closes on $22.4M Initial Public Offering

Actuate Therapeutics (NASDAQ: ACTU), a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers, recently announced the closing of its previously announced initial offering. The offering comprised 2,800,000 shares of the company’s common stock at a price of $8.00 per unit to the public, raising a total of $22,400,000 in gross proceeds before deductions. In addition, the company has granted a 30-day option to the underwriters to purchase up to 420,000 additional shares, representing 15% of the shares sold in the offering, solely to cover over-allotments, if any, at the initial…

ThursdayAug 15, 2024 11:51 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Publishes Q2 2024 Results

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today released its financial results for the second quarter ended June 30, 2024 (“Q2 2024”). The company also discussed the clinical development progress of Berubicin, its lead program, and TPI 287, its recently in-licensed abeotaxane for the treatment of brain malignancies. CNS Pharmaceutical expects to be able to release final topline data from its potentially pivotal trial of Berubicin in the first half of 2025. The trial is evaluating Berubicin in adult patients with…

ThursdayAug 15, 2024 11:03 am

QualityStocksNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports Q2 2024 Financial Results, Shares Business Update

Scinai Immunotherapeutics (NASDAQ: SCNI) is a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit. The company today published its financial results for the second quarter ended June 30, 2024, and provided a business update. Scinai plans to host a webinar to discuss its Q2 2024 results and business update on August 20, 2024, at 11 a.m. EDT/6 p.m. Israel Time. Recent highlights from Q2 2024 included the signing of an agreement to restructure a $29 million bank loan to equity and plans to regain Nasdaq compliance by…

Site Search

Company Search

Category: QualityStocksNewsBreaks